Wie hoch ist der Preis für RegeneRx Biopharmaceuticals, Inc. (RGRX)

Preis für RegeneRx Biopharmaceuticals, Inc. (RGRX) ist $0.0007

Wie hoch ist die Marktkapitalisierung für RegeneRx Biopharmaceuticals, Inc. (RGRX)

Marktkapitalisierung für RegeneRx Biopharmaceuticals, Inc. (RGRX) ist $1.05K

RegeneRx Biopharmaceuticals, Inc. (RGRX) Ausstehende Aktien

RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000. Its operations are headquartered in Rockville, Maryland.

Jahr	Ausstehende Aktien	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Ausstehende Aktien

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Ausstehende Aktien	Unterschied	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	0.00	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Unternehmen

Ausstehende Aktien

Unterschied

Land